Connection

Bo Cen to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Bo Cen has written about Xenograft Model Antitumor Assays.
Bo Cen
Connection Strength
0.327
Xenograft Model Antitumor Assays
  1. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anticancer Drugs. 2017 11; 28(10):1141-1149.
    View in: PubMed
    Score: 0.133
  2. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.117
  3. A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts. Drug Deliv. 2021 Dec; 28(1):1432-1442.
    View in: PubMed
    Score: 0.044
  4. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo. Drug Deliv. 2017 Nov; 24(1):471-481.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.